# QA Review: Sample Public PFAS Evidence Packet

Review role: skeptical buyer and expert QA reviewer  
Reviewed files: `sample-packet.md`, `source-index.md`, `evidence-matrix.csv`, `missing-documentation-register.csv`, `assumptions-and-limitations.md`  
Review date: July 7, 2026  
Review status: Internal QA only; packet not rewritten in this pass

## Scores

| Category | Score | Rationale |
| --- | ---: | --- |
| Overall score | 76/100 | Strong evidence architecture and conservative language, but still reads more like a technical demonstration than a polished premium consulting deliverable. |
| Buyer confidence score | 68/100 | A buyer would understand the value, but may question whether the public-source packet is substantial enough to justify a paid engagement without clearer work product polish, QA controls, and business-facing interpretation. |
| Expert-review readiness score | 84/100 | The packet is well organized for expert review. IDs, gaps, and matrices make QA feasible. Main weakness is lack of pinpoint citations, source capture controls, and explicit reviewer checkpoints. |

## Executive QA Judgment

This is a credible first sample of the Liberty Tree PFAS Evidence Packet. It demonstrates the right professional instincts: source indexing, conservative claims, clear limitations, no invented compliance conclusion, and visible gap conversion into next steps.

As a buyer-facing sample, it is not yet at the premium-consulting level implied by a $7.5k-$20k engagement. It currently proves that Liberty Tree can organize evidence. It does not yet fully prove that Liberty Tree can deliver a polished, buyer-ready decision support packet with a clear executive narrative, reviewer signoff discipline, and enough source detail for a third party to audit quickly.

The most valuable part of the packet is the gap framing. The sample turns weak public evidence into a structured supplier follow-up plan instead of apologizing for missing documents. That is the right commercial move. The next version should make the buyer feel: "This is exactly the map my team needs to avoid confusion, rework, and overclaiming."

## Paid Deliverable Assessment

### Does It Resemble A $7.5k-$20k Deliverable?

Partially.

At the low end of the range, this could support a paid diagnostic or pilot if it were packaged with a short executive memo, source capture appendix, and reviewer signoff page. At the high end, it is not there yet. A $20k buyer expects more visible diligence: controlled source snapshots, page-level citations, stronger summary tables, explicit QA marks, and a clearer distinction between "review performed" and "review pending."

What works:

- The structure feels serious and repeatable.
- The sample is source-indexed and avoids unsupported claims.
- The packet shows how missing information becomes a managed workstream.
- The evidence and gap IDs create a real review trail.

What keeps it below premium level:

- The sample has no cover memo or document control page with preparer/reviewer approvals.
- Citations are source-level, not page/section/line-level.
- The public source evidence is thin, and the packet does not yet compensate with enough buyer-facing explanation of why that thinness is normal and useful.
- The matrices are useful but visually plain; buyers may see data hygiene rather than premium advisory value.
- There is no explicit QA checklist showing exactly what an expert reviewer has approved or rejected.

## Buyer Confidence

Buyer confidence is moderate. The sample makes Liberty Tree look careful, which is essential in PFAS work. It does not make Liberty Tree look reckless, which is good.

The buyer concern would be: "Am I paying for a compliance deliverable or a documentation inventory?" The packet answers this in the limitations, but the value proposition needs to be sharper. The strongest buyer-facing message should be that the packet reduces risk by making undocumented assumptions visible, assigning follow-up work, and preserving a clean evidence trail.

The gaps are framed as value rather than failure in most places. `GAP-001`, `GAP-002`, `GAP-004`, and `GAP-005` are especially useful because they identify closure evidence. That is buyer-relevant. The packet should go one step further and show how each gap changes the next business decision: supplier follow-up, legal review, testing decision, customer response, or market-entry hold.

## Expert QA Readiness

An expert reviewer would know where to start:

- Check `SRC-001` against `EVID-001` and `EVID-002`.
- Check SDS/product-code mismatch in `SRC-002`, `SRC-003`, `GAP-002`, `EVID-003`, and `EVID-004`.
- Check whether `EVID-006` and `REG-CIT-001` are appropriately limited.
- Check whether `GAP-001` and `GAP-004` correctly avoid inferring formulation facts.
- Check whether recommended actions close the actual gaps.

The review path is strong, but not yet surgical. Expert reviewers should not have to hunt inside source documents. Each evidence row should include page number, SDS section, web page section, or quoted source excerpt. The current source IDs are enough for a first pass, but not enough for fast technical QA at scale.

## Traceability Assessment

Source traceability is adequate at the framework level and below premium level at the audit level.

Strengths:

- Every substantive claim generally ties to `SRC`, `EVID`, `GAP`, `ACTION`, or `REG-CIT`.
- Source IDs are stable and consistently used.
- The source index distinguishes product pages, SDS candidates, agency background, and regulatory sources.
- The packet avoids treating public source silence as evidence of absence.

Weaknesses:

- No page numbers, SDS section numbers in the CSV, downloaded file names, archive paths, hashes, or screenshot/PDF capture references.
- `source-index.md` lists URLs but not source capture method or whether each link was archived.
- `SRC-005` EPA background is useful context but should be clearly marked as non-evidentiary for product conclusions in every cross-reference where it appears.
- `REG-CIT-001` is indexed carefully, but the packet should separate "citation observed in SDS" from "citation applicable to product."
- The packet uses `NOTE-001` in scope, but there is no note index.

## Regulatory Language

The regulatory language is safer than it is commercially persuasive. That is preferable for an early PFAS packet, but the buyer-facing version should add a clearer regulatory review queue.

What is good:

- No compliance claim.
- No legal opinion.
- No invented requirement summary.
- eCFR citation is treated as indexed context, not applied law.
- The packet repeatedly says applicability has not been assessed.

What needs refinement:

- "Applicable Regulatory Framework" may be too strong as a section title for a sample where no applicability review occurred. Consider "Regulatory Citation Control" or "Regulatory Sources Pending Applicability Review" for demo packets.
- The packet should list the exact questions for legal/regulatory review: product category, distribution state/country, intentional-addition definition, substance scope, reporting/notification obligations, customer documentation obligations, and effective dates.
- The packet should distinguish public agency background from binding authority, official current source, and legal interpretation.

## Gap Framing

The gaps are one of the best parts of the sample. They are framed as controlled work items rather than deficiencies. The missing documentation register includes why each item matters and closure evidence, which makes the packet feel operational.

The next improvement is commercial framing. Each gap should answer:

- What decision is blocked?
- Who can close it?
- What evidence closes it?
- What happens if it remains open?
- Whether it is normal, unusual, or critical for this product type.

This would make gaps feel like paid advisory value rather than a list of missing files.

## AI Leverage Assessment

The packet shows AI leverage without exposing AI. The structured extraction, source indexing, matrix crosswalks, and gap/action conversion are exactly where AI can accelerate the work. The deliverable does not say "AI generated," and it does not expose prompts, model behavior, or automation details.

That said, the next version should show human QA controls more explicitly. A premium deliverable can be AI-assisted internally, but the artifact should visibly belong to a professional review process. Add preparer/reviewer fields, QA status, exception logs, and source verification marks.

## Thin, Generic, Or Uncertain Areas

- The executive summary is accurate but too short to sell the value of the packet.
- The sample scenario is useful but narrow; a buyer may wonder whether the format scales beyond one product.
- Product and supplier inventories are necessarily thin because public data is thin, but that should be explained as a deliberate demonstration of how public-source screening differs from client-source review.
- The SDS review matrix needs pinpoint source locations.
- The regulatory section is cautious, but it needs a more formal "pending regulatory review" structure.
- The source index lacks archival controls.
- The risk summary could better distinguish evidence-readiness risk from business/commercial risk.
- The recommended next steps are good but could include sequence, dependencies, and estimated effort level.

## Could This Support A $7.5k-$20k Engagement?

Yes, with positioning.

For a $7.5k diagnostic, the sample is close. It shows the core methodology and demonstrates a practical client outcome: evidence organized, weak points identified, supplier questions drafted, and risky assumptions isolated.

For a $15k-$20k engagement, the sample needs more polish and proof of review rigor. The buyer must see that Liberty Tree is not just summarizing documents but creating a defensible evidence file that procurement, EHS, legal, QA, and customer-response teams can all use.

The strongest commercial positioning is not "we determine compliance." It is: "we build the controlled evidence file your team needs before counsel, customers, suppliers, auditors, or regulators ask harder questions."

## Top 10 Fixes Ranked By Importance

1. Add pinpoint citations to every evidence row.
   Include page number, SDS section, table/field name, source excerpt, or web page section. This is the biggest upgrade for expert QA and buyer trust.

2. Add a formal document control and review signoff page.
   Include preparer, technical reviewer, QA reviewer, issue status, review dates, unresolved exceptions, and approval status.

3. Add a buyer-facing executive memo at the front.
   Summarize what the packet found, what remains unknown, why the gaps matter, and what decision path the buyer now has.

4. Add source capture controls.
   Record downloaded file names, access dates, archive locations, hashes where practical, and whether each public web source was saved as PDF/screenshot.

5. Convert the regulatory section into a review queue.
   Keep the conservative language, but add exact legal/regulatory questions and required source types so the section feels actionable rather than empty.

6. Strengthen gap value framing.
   For each gap, add business decision affected, closure owner, evidence needed, priority rationale, and consequence of leaving it open.

7. Add a QA checklist for expert reviewers.
   Include rows for product identity, SDS match, supplier identity, declaration scope, source capture, regulatory citation status, evidence/gap/action linkage, and prohibited claims.

8. Separate public-source demo limits from client-deliverable limits.
   The sample should say the public packet is intentionally constrained, while a client packet would use client records, supplier outreach, declarations, and controlled source files.

9. Add a one-page "evidence coverage dashboard."
   Show products, suppliers, SDS status, declaration status, testing status, regulatory review status, open gaps, and confidence distribution.

10. Improve matrix polish and consistency.
   Normalize confidence values, avoid mixed values like "Medium for source existence; Low for product-specific conclusion" in a single CSV cell, and move nuanced confidence reasoning into a notes column.

## Before Showing Prospects

Before this sample is prospect-ready, Liberty Tree should create a polished v2 that includes:

- Cover/control page.
- Executive memo.
- Evidence coverage dashboard.
- Pinpoint citations and source excerpts.
- Archived source capture references.
- QA checklist.
- More explicit regulatory review queue.
- Cleaner CSV schemas with notes columns.
- Gap-to-decision mapping.
- A short note explaining why a public-source demonstration intentionally contains unresolved gaps.

## Final QA Position

The sample packet is fundamentally sound. It shows a credible, careful approach and avoids the dangerous failure mode of overclaiming. The next iteration should focus less on adding more facts and more on making the existing facts feel controlled, reviewable, and commercially valuable.

The packet is good enough as an internal proof of method. It is not yet the prospect-facing flagship sample. With the top five fixes, it can plausibly support a paid pilot. With all ten fixes, it can begin to look like the front end of a $7.5k-$20k Liberty Tree evidence engagement.

